We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+24.92%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$9.73M
(+8.4%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
177.31%
Top 10 Holdings %
Top 10 Hldgs %
37.67%
Holding
493
New
153
Increased
113
Reduced
67
Closed
127
Top Buys
| 1 |
Procter & Gamble
PG
|
+$3.82M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$2.47M |
| 3 |
iShares Biotechnology ETF
IBB
|
+$2M |
| 4 |
Ulta Beauty
ULTA
|
+$1.86M |
| 5 |
MON
Monsanto Co
MON
|
+$1.82M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$7.18M |
| 2 |
Biogen
BIIB
|
+$4.33M |
| 3 |
Cal-Maine
CALM
|
+$3.64M |
| 4 |
Apple
AAPL
|
+$2.74M |
| 5 |
ALR
Alere Inc
ALR
|
+$2.22M |
Sector Composition
| 1 | Healthcare | 39.95% |
| 2 | Consumer Staples | 5.72% |
| 3 | Consumer Discretionary | 5.14% |
| 4 | Technology | 3.35% |
| 5 | Materials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Kohl's
KSS
$1.98B
| $219K | 0.17% |
5,000
-1,500
| -23% | -$62.8K |
|
102
PUT
Novavax
NVAX
$1.35B
| $219K | 0.17% |
+11,575
| New | +$1.49M |
|
103
PUT
Five Below
FIVE
$10.9B
| $218K | 0.17% |
57,800
+5,000
| +9% | +$231K |
|
|
CLVS
104
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $212K | 0.17% |
54,400
+30,000
| +123% | +$644K |
|
105
Silicon Motion
SIMO
$9.24B
| $202K | 0.16% |
+3,902
| New | +$203K |
|
106
PUT
Alibaba
BABA
$282B
| $201K | 0.16% |
25,100
+14,000
| +126% | +$1.3M |
|
|
CELG
107
CALL
DELISTED
Celgene Corp
CELG
| $201K | 0.16% |
186,300
+161,300
| +645% | +$17.5M |
|
|
IM
108
DELISTED
Ingram Micro
IM
| $196K | 0.16% |
+5,500
| New | +$191K |
|
|
109
Novavax
NVAX
$1.35B
| $187K | 0.15% |
+4,500
| New | +$581K |
|
|
NIHD
110
DELISTED
NII Holdings, Inc. Common Stock
NIHD
| $183K | 0.15% |
55,000
+25,000
| +83% | +$73.9K |
|
|
AERI
111
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $177K | 0.14% |
+14,900
| New | +$329K |
|
112
CALL
Mondelez International
MDLZ
$78.8B
| $176K | 0.14% |
191,600
+115,600
| +152% | +$5.07M |
|
113
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
| $175K | 0.14% |
48,600
+43,600
| +872% | +$4.11M |
|
114
CALL
Humana
HUM
$46.4B
| $174K | 0.14% |
34,600
+5,600
| +19% | +$972K |
|
|
SVVC
115
DELISTED
Firsthand Technology Value Fund, Inc. Common Stock
SVVC
| $173K | 0.14% |
22,238
| – | – |
|
116
CALL
Colgate-Palmolive
CL
$75.3B
| $168K | 0.13% |
229,100
-74,900
| -25% | -$5.54M |
|
|
ISEE
117
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $168K | 0.13% |
3,634
-636
| -15% | -$35.9K |
|
|
CELG
118
PUT
DELISTED
Celgene Corp
CELG
| $163K | 0.13% |
+50,000
| New | +$5.41M |
|
119
American International
AIG
$41.4B
| $160K | 0.13% |
+2,700
| New | +$154K |
|
120
PUT
Bank OZK
OZK
$5.8B
| $160K | 0.13% |
57,000
+37,000
| +185% | +$1.4M |
|
|
RPTP
121
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $158K | 0.13% |
27,700
-14,400
| -34% | -$102K |
|
|
TWX
122
CALL
DELISTED
Time Warner Inc
TWX
| $154K | 0.12% |
96,800
+56,300
| +139% | +$4.4M |
|
123
CALL
Verizon
VZ
$183B
| $151K | 0.12% |
50,000
| – | – |
|
|
124
PUT
Biogen
BIIB
$30.8B
| $149K | 0.12% |
20,000
-5,000
| -20% | -$1.48M |
|
|
AGN
125
PUT
DELISTED
Allergan plc
AGN
| $149K | 0.12% |
6,000
-4,000
| -40% | -$977K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2016 Portfolio in Review
As of Q3 2016, FT Options held 493 positions worth $126M, up 8.4% from $116M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
FT Options deployed $224M of net new capital in Q3 2016, opening 153 new positions and adding to 113 existing holdings. Its largest new stake was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 41% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $2.74M trimmed.
- FT Options's largest Q3 2016 buy was iShares Biotechnology ETF: 21,000 shares worth $2.03M.
- FT Options added most to Procter & Gamble in Q3 2016, an estimated $3.82M increase.
- FT Options's biggest Q3 2016 reduction was Apple, cutting an estimated $2.74M.
- FT Options fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $7.18M.
- FT Options's ten largest holdings make up 38% of its $126M portfolio in Q3 2016.
- FT Options opened 153 new positions and closed 127 in Q3 2016.
- FT Options's portfolio value rose 8.4% quarter-over-quarter to $126M.
Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.